Diabetes News
2017-11-29
Qvin’s Q-Pad™ Earns Special Mention in TIME’s Best Inventions 2024
Qvin's Q-Pad™ recognized in TIME's 'Best Inventions 2024' for Advancing Women's HealthMOREBeta Bionics Launches iLet Bionic Pancreas with Abbott FreeStyle Libre 3 Plus Sensor
Beta Bionics launches iLet Bionic Pancreas with FreeStyle Libre 3 Plus, offering real-time, autonomous glucose monitoring for type 1 diabetes users.MOREFTC Sues Major Pharmacy Benefit Managers for Inflating Insulin Prices
The lawsuit targets Optum Rx, Caremark, and Express Scripts, accusing them of unfair practices that raise insulin costs, while the companies deny wrongdoingMORETandem t:X2 Insulin Pump Now Compatible with Lyumjev in EU
Enhances flexibility and quality of life for diabetes patientsMOREEversense 365 Continuous Glucose Monitoring System Receives FDA Clearance: The First One-Year CGM
Revolutionizing diabetes management with a full-year sensor.MOREDexcom CGM Worn in Space for the First Time!
Astronauts are taking their diabetes tech to new heights—literally! For the first time ever, the Dexcom G6 Continuous Glucose Monitoring (CGM) system is being worn in space as part of the Polaris Da...MOREFDA Approves Embecta’s New Insulin-Delivery System for Both Type 1 and Type 2 Diabetes
In a significant development for diabetes care, Embecta Corp. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its groundbreaking disposable insulin-delivery system, ...MOREMedtronic Announces FDA Approval of Simplera™ CGM and Global Partnership with Abbott
The Simplera™ continuous glucose monitor (CGM) was approved by the Food and Drug Administration (FDA) on August 7, 2024. According to a press release from Medtronic, Simplera™ is Medtronic’s fir...MOREIs the Rising Use of Cannabis Among U.S. Adults with Diabetes a Health Concern?
According to a recent study published in the July 22, 2024 issue of Diabetes Care, the percentage of adult Americans with diabetes who use cannabis increased by 33.7% between 2021 and 2022. The findin...MOREDiamyd’s Type 1 Diabetes Prevention Therapy Gets FDA Fast Track
Diamyd Medical is making waves with its innovative therapy, Diamyd, designed to prevent type 1 diabetes. Recently, the U.S. Food and Drug Administration (FDA) granted Diamyd its second Fast Track desi...MOREAbbott Gets FDA Clearance for Two Over-the-Counter CGMs
Abbott Laboratories announced on June 10, 2024 that two new over-the-counter (OTC) continuous glucose monitoring (CGM) devices had received FDA clearance. These two devices—one aimed at health-consc...MOREDexcom Launches the G7 with Apple Watch Integration
On June 5, 2024, Dexcom announced that its G7 continuous glucose monitor (CGM) now connects directly to the Apple Watch in the U.S. Dexcom first revealed this implementation in March. With its officia...MOREThe Price of Uncertainty: Unveiling the Impact of Unexpected Type 1 Diabetes Diagnoses
Sanofi commissioned a study to determine the impact of an unexpected type 1 diabetes diagnosis. Learn all about what they discovered.MOREJDRF Rebrands as Breakthrough T1D to Accelerate Type 1 Research and Advocacy
On June 4, 2024, the Juvenile Diabetes Research Foundation (JDRF) announced that Breakthrough T1D was the new name for the organization. During the organization’s annual Government Day meeting i...MOREFDA Approves CamAPS FX Hybrid Closed-Loop Insulin Delivery App
The US Food and Drug Administration (FDA) has approved a hybrid, closed-loop, insulin-delivery Android app. On May 29, 2024, CamDiab, a company that creates state-of-the-art diabetes management techno...MORETandem Mobi Pump and the Dexcom G7 CGM Are Now Connected
On May 29, 2024, Tandem Diabetes Care and Dexcom, Inc. announced that the Dexcom G7 continuous glucose monitor (CGM) and the Tandem Mobi insulin pump are now completely compatible. Tandem Mobi connect...MORENovo’s Once-Weekly Insulin Is a No-Go with FDA Advisory Panel
Advisers to the U.S. Food and Drug Administration (FDA) voted 7–4 not to approve Novo Nordisk’s once-weekly, experimental insulin known as Awiqli, citing a lack of benefit over risk. The FDA h...MOREThe twiist Automated Insulin Delivery System Receives FDA Clearance
On March 18, 2024, Sequel Med Tech announced that its partner—DEKA Research & Development Corp.—received FDA clearance for the twiist Automated Insulin Delivery (AID) system. Using the FDA-cle...MOREDexcom Introduces Direct-to-Apple-Watch Feature for its G7 CGM
Dexcom recently introduced a direct-to-Apple-Watch feature for its G7 continuous glucose monitor (CGM) users. This means G7 will be the only CGM system that can connect directly to Apple Watch without...MOREPayment Assistance and Savings Program Extended for the Eversense E3 CGM
Ascensia Diabetes Care and Senseonics have extended their Eversense Payment Assistance and Simple Savings (PASS) program—aimed to help people in the U.S. more affordably access the Eversense E3 cont...MOREThe Tandem Mobi is Now Available
World’s Smallest Automated Insulin Delivery System Lets People With Diabetes Experience the Benefits of Control-IQ TechnologyMOREt:slim X2 Becomes First Automated-Insulin-Delivery System to Fully Integrate With the FreeStyle Libre 2 Plus CGM
t:slim X2 becomes first automated-insulin-delivery system to fully integrate with the FreeStyle Libre 2 Plus continuous glucose monitoring system MOREADA Standards of Care 2024: So What’s New?
Diabetes research, technology, and treatments are rapidly changing. Here's what you need to know about the 2024 Standards of Care.MOREDexcom G7 Now Integrated with T:slim X2
Tandem’s T:slim X2 insulin pump is the first automated insulin delivery system to fully integrate with Dexcom’s G7 continuous glucose monitoring system.MOREBenefits of Using a Dexcom G7 CGM During Pregnancy
Managing diabetes during pregnancy can be tough, but Dexcom Chief Operating Officer Jake Leach shares how a CGM can help.MOREGoodRx Announces New Way for People to Access Lantus for $35
GoodRx partnered with Sanofi to offer $35 insulin coupons to all, regardless of their insurance status, for use at pharmacies nationwide. MORENew Program Recognizes Leaders In Diabetes Care
Received stellar diabetes care? Encourage your providers to apply to be recognized as leaders in diabetes care.MOREVertex VX-880 Clinical Results Lead To Insulin-Independence
Here's what you need to know about Vertex's recent results from their stem-cell therapy for type 1 diabetes.MOREKetogenic Diet for Kids with Diabetes Carries Risk
The American Academy of Pediatrics warns against a ketogenic diet, a popular low-carbohydrate diet, for children with diabetes.MOREDexcom ONE Now Available in France
Dexcom ONE, a continuous glucose monitoring (CGM) system, is now available for people with diabetes in France.MOREBeyond Type 2 Expands to Provide Resources to Canada
Canadians can now share their stories, get connected to the community and find critical resources on all things type 2 diabetes. MOREHow You Can Try a Dexcom CGM for Free
Learn why continuous glucose monitors (CGMs) are beneficial and how you can try the free 10-day Dexcom trial program.MORET1D Clinical Trial Search Engine Now Available In Spanish
Beyond Type 1 collaborates with Antidote Technologies and JDRF to launch the first-ever Spanish-language clinical trial search engine for type 1 diabetes.MOREProject IMPACT: Bringing CGM Access to a Pharmacy Near You
Interview with Robert E. Nichols, PharmD, BCPS, Clinical Pharmacist, who is participating in the pilot program for better CGM access. MOREBeyond Type Run Marathon Team Reaches New Milestones in 2023
Beyond Type Run, the stereotype-smashing team of runners proves anybody living with diabetes can go the distance despite their diagnosis.MOREMoms’ Night Out Aims to Support Caregivers of People with Type 1 Diabetes
“Moms’ Night Out” expands after exciting launch. Attend an upcoming event for mothers of children with diabetes in these three cities!MOREJDRF’s Children’s Congress: Finding A Cure For Type 1 Diabetes
Learn more about JDRF, its mission behind the biannual Children’s Congress and the impact of this year's event.MORETandem’s Mobi Approved by the FDA
Tandem’s newest insulin pump, Mobi, was approved by the FDA for people with diabetes age six and up. Here's what you need to know!MOREA Year in Review: Advancements in Diabetes Tech + Research
This session reviewed the advances and discoveries in research and technology for people living with diabetes over the past year.MORESenseonics + UnitedHealthcare Expanding CGM Access
Senseonics announced that UnitedHealthCare will now cover their Eversense E3 implantable CGM, starting July 1, 2023.MOREMedtronic’s MiniMed 780G Receives FDA Approval
The FDA has approved Medtronic’s MiniMed 780G, the newest automated insulin dosing (AID) system on the market. MOREEli Lilly’s Baqsimi Acquired by Amphastar: What This Means for People With Diabetes
Eli Lilly’s nasal glucagon, Baqsimi, has been acquired by Amphastar. Here’s what you should know about the change and its significance.MOREMark Cuban’s Cost Plus Drugs Makes Diabetes Products More Affordable
Mark Cuban's Cost Plus Drugs Company just announced that they offer Janssen's Invokana, Invokamet and Invokamet XR for type 2 diabetes.MOREWhy Diabetes Should be Screened by Age Instead of Weight
Many cases of diabetes may be missed by screening only by weight instead of age, especially for some racial and ethnic groups.MORECalifornia Partners with Civica Rx to Make More Affordable Insulin
California has signed a contract with Civica Rx to make more affordable insulin for Americans with diabetes. Here’s what you should know about their partnership, CalRx.MORESanofi to Slash Price of Lantus by 78%, Cap Out-of-Pocket Costs to $35
Sanofi has capped monthly out-of-pocket costs for Lantus to $35 for all with commercial insurance and will cut the price of Lantus by 78%, effective January 1, 2024. MORENovo Nordisk to Slash Insulin Prices by over 65%
Novo Nordisk announced that starting January 1st, 2024 they will be lowering the list price of several of their insulins by 65-70%.MOREFreestyle Libre 2 and Freestyle Libre 3 to Integrate with Automated Insulin Delivery Systems
Abbott, makers of the Freestyle Libre 2 and 3, modified their sensors to enable integration with automated insulin delivery systems. Here’s what you should know!MORE$25 List Price + $35 Copay Caps: Lilly’s New Insulin Cost Reductions
On March 1, 2023, insulin manufacturer Lilly announced expanded insulin cost-saving measures for people with and without health insurance coverage.MOREThis New App is Designed to Make Tracking Your Insulin Easier
If you use Lilly brand insulin, this new connected platform is designed to make tracking your diabetes data a lot easier. MORESay Hello to BeyondType2.org in French, German and Italian!
BeyondType2.org now offers critical resources in five languages for people living with and impacted by type 2 diabetes.MOREDiabetes + Dementia: Using Nasal Insulin to Improve Brain Function
With rising rates of obesity in both type 1 and type 2 diabetes, understanding the impact on long-term brain health and function is critical.MOREWomen + Exercise: It’s Complicated
Women living with type 1 diabetes are told exercise will help better manage their diabetes. That’s easier said than done. MOREReaching Everyone — Health Disparities in Physical Activity
People living with diabetes are told to just exercise more to better manage their diabetes. Here is why its not that simple. MOREAnother Reminder that Racial/Ethnic Inequality Exists in Diabetes Care
Despite the variety of diabetes medications and technology, race and ethnicity still weigh heavily on a person’s access to these life-saving tools.MORERace, Racism, and Diabetes Research
Diabetes care and research is still drastically impacted by racist practices. It’s time to call the racism out. MOREResearch: Practical Use of Closed-Loop Insulin Pumps
Closed-loop insulin pump technology is a game-changer for those taking insulin. Here are essential tips to using them in day-to-day life.MOREAccess to Insulin: In the United States
Despite the growing variety of insulin and technology, access to this life-saving drug continues to be a dire problem in the United States.MOREAccess to Insulin: In Low-Income Countries
In many countries, a person with diabetes may walk for four days to get a vial of short-acting insulin and seven to 10 days for long-acting.MOREPromising New Drug Leads to 22.5% Weight Loss in Adults Living with Obesity
The latest study on a new drug is making headlines for its impressive ability to help patients lose weight.MOREStem Cell Therapy for Type 1 Diabetes: Patient Achieved Insulin Independence on Day 270
A patient in the Vertex Pharmaceutical’s clinical trial using stem-cell therapy to treat type 1 diabetes has achieved insulin independence on Day 270 of the trial. MOREThe Affordable Insulin Now Act: A Step Toward Federal Legislation
The Affordable Insulin Now Act, if passed in its current form, could help bring down the cost of insulin for millions of insured people with diabetes.MOREFreeStyle Libre 2 Now More Easily Accessible for Military Members Through TRICARE
Military members with TRICARE now have easier access to Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM).MORECOVID-19 Pushes FDA Approval of Breakthrough Device Designation for Dexcom CGM in Hospital Settings
The FDA has granted Breakthrough Device Designation for Dexcom CGM in hospital settings after the pandemic highlighted essential care needs for patients with diabetes.MOREEversense E3 Continuous Glucose Monitor Gains FDA Approval, Offers Extended Wear-Time
The Eversense E3 continuous glucose monitor (CGM) is an exciting advancement for the diabetes community, with improved wear-time and accuracy.MOREOmnipod 5 Receives FDA Approval
Omnipod 5, a closed-loop tubeless insulin pump with smartphone control that integrates with the Dexcom G6 continuous glucose monitor, has now received FDA approval.MOREInside the Drug Pricing Investigation from the House Oversight and Reform Committee
The results of the most recent report from the committee make things clear for the United States — the need for access to affordable healthcare is direr than ever.MOREThe Potential Impact of Build Back Better on American Healthcare
Dive into the basics of Build Back Better, why people with diabetes should follow the bill as it progresses, and the impact it could have on your health.MOREMark Cuban’s New Online Pharmacy Provides Affordable Access to Some Common Prescription Drugs
Mark Cuban's latest investment in the pharmaceutical industry offers common generic prescription medications (not including insulin) at a fraction of the cost.MOREA Win for T1D in California: Senate Bill 97 Signed Into Law
The bill requires type 1 diabetes informational materials to be developed for the parents and guardians of pupils in California schools.MOREBeyond Type 1 Launches Web Platform in Arabic
Diabetes information, stories, and news are now available in Arabic at ar.beyondtype1.org.MORECOVID-19 Vaccines For Kids Ages 5 to 11 With Diabetes: What to Know
COVID-19 vaccines are now available for kids age 5+! Learn about safety and managing side effects for kids with type 1 diabetes.MOREStem-Cell Therapy for Type 1 Diabetes Reduced Patient’s Insulin Needs by 91%
The early results of a clinical trial using stem-cell therapy to treat type 1 diabetes reduced the patient’s insulin needs by 91%.MORELilly Announces Lower List price for Insulin Lispro
The company will lower the list price of the generic version of Humalog in the U.S. by an additional 40 percent starting January 1, 2022.MORELilly Issues Voluntary Nationwide Recall of One Lot of Glucagon Emergency Kit
Lilly announced the voluntary recall of lot D239382D, Expiration April 2022 of Glucagon Emergency Kits.MOREThe Latinx Diabetes Initiative Provides Culturally Tailored Care To Latinx Patients With Diabetes
Andreina Millan Ferro is centering culturally sensitive diabetes care for Latinx patients with diabetes at the Latinx Diabetes Initiative.MOREYarishdy Mora Is Empowering Youth Through Diabetes Education In Mexico
Yarishdy Mora is the director of the Youth Health Program for Project HOPE in Mexico. She creates platforms that help youth learn about diabetes. MOREOverweight Adults to Now Be Screened for Type 2 Diabetes At 35
The U.S. Preventive Services Task Force now recommends overweight and obese adults to get screened for Type 2 diabetes at the age of 35.MOREAbbott’s FreeStyle Libre 2 App Receives FDA Clearance
On August 2, 2021, the FDA approved the FreeStyle Libre 2 app for adults and children with diabetes, allowing user to access glucose readings directly from their iPhone.MOREProviding Culturally Sensitive LGBTQ+ Diabetes Health Care
Culturally sensitive LGBTQ+ diabetes health care can decrease stigma and advance diabetes care access for the LGBTQ community. MOREHigh Risk Pregnancy – Mitigating Risks for Type 1 Diabetes + Black Maternal Health Outcomes
Ariel Lawrence, a diabetes advocate and Black mother with type 1 diabetes, shares how she navigated her pregnancy. MOREAddressing Disparities in Pediatric Diabetes Treatment In Philadelphia
Terri Lipman shares how incorporating community health workers can tackle disparities in pediatric diabetes treatment. MOREFDA Issues CRL for Teplizumab, Investigational Candidate to Delay the Onset of T1D
The FDA issues a complete response letter to Provention Bio as part of an update for Teplizumab to delay the onset of type 1 diabetes.MORECombating Diabetes Disparities Among The Hispanic Population
At ADA 2021, David Marrero discusses how culturally tailored care can combat diabetes disparities among the Hispanic population.MOREWalmart Launches Lower-Cost Analog Insulin: ReliOn NovoLog
ReliOn NovoLog will be available at Walmart and Sam's Club pharmacies for $72.88 per vial and $85.88 per box of five FlexPens.MOREPreliminary Findings On Depression Among African American and Latino Parents of Children With T1D
Samantha Carreon shares preliminary data on the TEAM study which found higher rates of depression among African American and Latino parents.MOREMaking Broadway More Accessible With JP Qualters
JP Qualters shares his experience on Broadway as a person living with type 1 diabetes and his aspirations for the theater industry.MOREZegalogue® Is Now Commercially Available In The United States
Zegalogue®, also known as dasiglucagon, is now commercially available in the U.S. for the treatment of severe hypoglycemia.MOREMedicare Loosens Restrictions on Continuous Glucose Monitor Coverage
Medicare revised its local coverage determination policy to remove requirements for continuous glucose monitor coverage.MORECOVID-19 Vaccines And Diabetes: Vaccine Access Issues For People Of Color
Communities of color with diabetes face a myriad of barriers when it comes to vaccine access. Experts share how the U.S. can achieve vaccine equity.MOREMichelle L. Litchman Focuses On Diabetes Program Accessibility For People Who Are Deaf
Michelle L. Litchman was named a Betty Irene Moore Nurse Fellow. She will focus on diabetes program accessibility for people who are deaf.MORETest Strip Subscription Guide
We compiled a rundown of popular companies that offer test strip subscription services and researched each of them to give you some important info.MOREOmnipod 5 Pivotal Trial Data Published
Data from the pivotal trial shows that the Omnipod 5 improves time-in-range, and reduces HbA1c and mean glucose levels. MOREBreaking News From ATTD 2021
This year, ATTD 2021 will be held virtually where developers and clinicians will present their new diabetes technology and research.MORESurvey Finds the Pandemic Increased Mental Health Concerns Among People With Diabetes
Cecelia Health conducted a survey that revealed increased mental health concerns among people with diabetes during the COVID-19 pandemic. MORECombating Bullying: How One Person With Diabetes Fought To Test Her Blood Sugar In The Workplace
Sheri Byrne shares her experience on how she fought workplace bullying due to diabetes and advocated for herself.MOREBigfoot Unity™ Diabetes Management System Receives The Green Light From The FDA
Bigfoot Unity™, a one-of-a-kind diabetes management system with smart pen caps received FDA approval on May 10, 2021 and will reach select diabetes clinics this spring. MOREAsian Isn’t A Monolith: Why More Specific Data Matters in Diabetes Research
Data on how diabetes impacts specific ethnic groups could help us better support people within Asian American Pacific Islander communities.MOREType 1 Diabetes + Ramadan: Here’s How a Few People Are Observing
People with diabetes face their own set of challenges when observing Ramadan. Two people with diabetes share their experiences. MOREThe PROTECT Study
The PROTECT Study aims to understand how the investigational medicine, teplizumab, works in children and young adults who have recently been diagnosed with T1D, as well as assessing if there are any s...MORE